164 related articles for article (PubMed ID: 15102606)
1. Poxvirus vaccines for cancer and HIV therapy.
Essajee S; Kaufman HL
Expert Opin Biol Ther; 2004 Apr; 4(4):575-88. PubMed ID: 15102606
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy with poxvirus vectors.
Moroziewicz D; Kaufman HL
Curr Opin Mol Ther; 2005 Aug; 7(4):317-25. PubMed ID: 16121697
[TBL] [Abstract][Full Text] [Related]
3. Poxviruses as vectors for cancer immunotherapy.
Kwak H; Hörig H; Kaufman HL
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):161-8. PubMed ID: 12669450
[TBL] [Abstract][Full Text] [Related]
4. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
5. Recombinant poxviruses as mucosal vaccine vectors.
Gherardi MM; Esteban M
J Gen Virol; 2005 Nov; 86(Pt 11):2925-2936. PubMed ID: 16227213
[TBL] [Abstract][Full Text] [Related]
6. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.
Gómez CE; Nájera JL; Krupa M; Esteban M
Curr Gene Ther; 2008 Apr; 8(2):97-120. PubMed ID: 18393831
[TBL] [Abstract][Full Text] [Related]
7. Poxvirus cancer therapy.
Gilbert PA; McFadden G
Recent Pat Antiinfect Drug Discov; 2006 Nov; 1(3):309-21. PubMed ID: 18221156
[TBL] [Abstract][Full Text] [Related]
8. Poxviral vectors for cancer immunotherapy.
Kim JW; Gulley JL
Expert Opin Biol Ther; 2012 Apr; 12(4):463-78. PubMed ID: 22413824
[TBL] [Abstract][Full Text] [Related]
9. Poxvirus vectors as HIV/AIDS vaccines in humans.
Gómez CE; Perdiguero B; Garcia-Arriaza J; Esteban M
Hum Vaccin Immunother; 2012 Sep; 8(9):1192-207. PubMed ID: 22906946
[TBL] [Abstract][Full Text] [Related]
10. Poxvirus-based vectors as vaccine candidates.
Tartaglia J; Pincus S; Paoletti E
Crit Rev Immunol; 1990; 10(1):13-30. PubMed ID: 2407263
[TBL] [Abstract][Full Text] [Related]
11. Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse model.
Offerman K; Deffur A; Carulei O; Wilkinson R; Douglass N; Williamson AL
BMC Genomics; 2015 Jul; 16(1):510. PubMed ID: 26153454
[TBL] [Abstract][Full Text] [Related]
12. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
Taylor J; Paoletti E
Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
[TBL] [Abstract][Full Text] [Related]
13. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
[TBL] [Abstract][Full Text] [Related]
14. The role of poxviruses in tumor immunotherapy.
Kaufman HL
Surgery; 2003 Nov; 134(5):731-7. PubMed ID: 14639347
[No Abstract] [Full Text] [Related]
15. Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.
Conrad SJ; Liu J
Methods Mol Biol; 2019; 1937():189-209. PubMed ID: 30706397
[TBL] [Abstract][Full Text] [Related]
16. Recombinant viruses as a tool for therapeutic vaccination against human cancers.
Bonnet MC; Tartaglia J; Verdier F; Kourilsky P; Lindberg A; Klein M; Moingeon P
Immunol Lett; 2000 Sep; 74(1):11-25. PubMed ID: 10996623
[TBL] [Abstract][Full Text] [Related]
17. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
[TBL] [Abstract][Full Text] [Related]
18. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
19. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors.
Mastrangelo MJ; Lattime EC
Cancer Gene Ther; 2002 Dec; 9(12):1013-21. PubMed ID: 12522440
[TBL] [Abstract][Full Text] [Related]
20. The potential role of fowlpox virus in rational vaccine design.
Beukema EL; Brown MP; Hayball JD
Expert Rev Vaccines; 2006 Aug; 5(4):565-77. PubMed ID: 16989636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
